Celltrion Gets Go-Ahead For Remsima Trials In China, Mulls JV
Celltrion has received approval to begin clinical trials of its biosimilar infliximab in China and also filed IND applications for other biosimilar products with the CFDA, accelerating plans to enter the world’s second biggest pharma market as it propels efforts for global leadership in the biosimilar space.
You may also be interested in...
Biosimilar specialists Celltrion and Samsung Bioepis are poised to start competing in China, which they see as another promising market for their biosimilars amid the Chinese government's increasing policy support for biologics and generics, and rising competition elsewhere. Part of their tailored entry approach includes striking deals with local partners.
Bilateral ties between South Korea and China may have slumped to a new low, but that doesn’t seem to have deterred deals between firms in the two nations in the biotech space. Scrip takes a closer look at the deal-making flow and whether it is sustainable.
With Tongfang Kontafarma's cancelation of an equity investment, Binex appears to have become the first South Korean biologics firm to be hit by an increasingly strained relationship between South Korea and China. The two companies will instead establish a Chinese joint venture.